Moleculin Biotech is trading 11.87% up now at $0.80 after investors responded to encouraging interim MIRACLE trial data for Annamycin.
- Complete remission rates were 43% and 36% in the two treatment arms, versus 12% for control.
- Zero cardiotoxicity was reported across 90 independently reviewed patients.
- The H.C. Wainwright presentation highlighted continued trial progress and upcoming regulatory milestones, but the conference source does not explicitly quantify its impact on September 14 trading.